<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="39867">Valproic acid</z:chebi> (VPA) inhibits <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase activity and induces differentiation of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) blasts in vitro </plain></SENT>
<SENT sid="1" pm="."><plain>We observed clinical responses to VPA in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we report follow-up data on 75 patients </plain></SENT>
<SENT sid="3" pm="."><plain>Of these, 66 were started on VPA monotherapy, with later addition of <z:hpo ids='HP_0000001'>all</z:hpo>-trans <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> (ATRA) in patients who did not respond or relapsed </plain></SENT>
<SENT sid="4" pm="."><plain>Nine patients were treated with VPA + ATRA from the start </plain></SENT>
<SENT sid="5" pm="."><plain>Median treatment duration was 4 months for VPA and 2 months for ATRA </plain></SENT>
<SENT sid="6" pm="."><plain>Hematological improvement, according to international working group criteria for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, was observed in 18 patients (24%) </plain></SENT>
<SENT sid="7" pm="."><plain>Median response duration was 4 months </plain></SENT>
<SENT sid="8" pm="."><plain>ATRA exerted no additional effect in patients receiving the combination from the start or benefited primary VPA nonresponders </plain></SENT>
<SENT sid="9" pm="."><plain>However, of ten VPA responders who relapsed, four achieved a second response after addition of ATRA </plain></SENT>
<SENT sid="10" pm="."><plain>Response rates were strongly dependent on disease type according to WHO classification </plain></SENT>
<SENT sid="11" pm="."><plain>We found a response rate of 52% in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with a <z:mpath ids='MPATH_458'>normal</z:mpath> blast count (<z:hpo ids='HP_0004864'>refractory sideroblastic anemia</z:hpo>, refractory cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, and refractory sideroblastic cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath>) </plain></SENT>
<SENT sid="12" pm="."><plain>The response rate was 6% in <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts (I + II), 16% in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, and 0% in <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>Bone marrow blast count was the only variable that predicted responses </plain></SENT>
<SENT sid="14" pm="."><plain>We conclude that VPA is clinically useful in low-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="15" pm="."><plain>For patients with high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, VPA may be combined with chemotherapy or demethylating drugs </plain></SENT>
<SENT sid="16" pm="."><plain>If patients relapse after an initial response to VPA, ATRA has the potential to induce a prolonged second response </plain></SENT>
</text></document>